These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 28994285)
1. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. Hickey JW; Vicente FP; Howard GP; Mao HQ; Schneck JP Nano Lett; 2017 Nov; 17(11):7045-7054. PubMed ID: 28994285 [TBL] [Abstract][Full Text] [Related]
2. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Rhodes KR; Green JJ Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074 [TBL] [Abstract][Full Text] [Related]
3. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma. Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372 [TBL] [Abstract][Full Text] [Related]
4. Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties. Hickey JW; Isser AY; Vicente FP; Warner SB; Mao HQ; Schneck JP Biomaterials; 2018 Dec; 187():105-116. PubMed ID: 30312851 [TBL] [Abstract][Full Text] [Related]
5. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391 [TBL] [Abstract][Full Text] [Related]
6. DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy. Sun L; Shen F; Xiong Z; Yang H; Dong Z; Xiang J; Gu Q; Ji Q; Fan C; Liu Z J Am Chem Soc; 2022 May; 144(17):7634-7645. PubMed ID: 35438987 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation. Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393 [TBL] [Abstract][Full Text] [Related]
8. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Eggermont LJ; Paulis LE; Tel J; Figdor CG Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519 [TBL] [Abstract][Full Text] [Related]
9. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses. Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669 [TBL] [Abstract][Full Text] [Related]
10. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses. Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708 [TBL] [Abstract][Full Text] [Related]
11. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy. Hou F; Guo Z; Ho MT; Hui Y; Zhao CX ACS Nano; 2024 Mar; 18(12):8571-8599. PubMed ID: 38483840 [TBL] [Abstract][Full Text] [Related]
12. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Sunshine JC; Perica K; Schneck JP; Green JJ Biomaterials; 2014 Jan; 35(1):269-277. PubMed ID: 24099710 [TBL] [Abstract][Full Text] [Related]
13. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of T-Cell Activation by Oscillatory Forces and Engineered Antigen-Presenting Cells. Majedi FS; Hasani-Sadrabadi MM; Thauland TJ; Li S; Bouchard LS; Butte MJ Nano Lett; 2019 Oct; 19(10):6945-6954. PubMed ID: 31478664 [TBL] [Abstract][Full Text] [Related]
15. Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation. Chen JY; Agrawal S; Yi HP; Vallejo D; Agrawal A; Lee AP Adv Healthc Mater; 2023 May; 12(12):e2203163. PubMed ID: 36645182 [TBL] [Abstract][Full Text] [Related]
16. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. East JE; Sun W; Webb TJ J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308 [TBL] [Abstract][Full Text] [Related]
17. Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy. Yang W; Deng H; Zhu S; Lau J; Tian R; Wang S; Zhou Z; Yu G; Rao L; He L; Ma Y; Chen X Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33310853 [TBL] [Abstract][Full Text] [Related]
18. T Cells on Engineered Substrates: The Impact of TCR Clustering Is Enhanced by LFA-1 Engagement. Benard E; Nunès JA; Limozin L; Sengupta K Front Immunol; 2018; 9():2085. PubMed ID: 30279692 [TBL] [Abstract][Full Text] [Related]